Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Use of Formula Fortified With DHA in Infants With Cystic Fibrosis (DHA)

This study has been completed.
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Brian O'Sullivan, University of Massachusetts, Worcester Identifier:
First received: September 13, 2007
Last updated: February 16, 2012
Last verified: February 2012

The hypothesis of this study is that feeding infants diagnosed with CF via newborn screening a formula enhanced with a specific fish-oil fatty acid known as DHA will improve growth and decrease pancreatic dysfunction (as measured by human fecal elastase-1 in stool) over the first year of life.

Briefly, infants diagnosed with CF in the first month of life whose parents chose not to breast feed their babies will be invited to enroll in a study comparing a standard commercial infant formula (Enfamil) with a formula enriched with arachidonic acid (AA) and docosahexaenoic acid (DHA). The study formula has 3 times the amount of DHA available in commercially available formulas. Infants will have monthly tests of stool elastase and blood work at entry, 3, 6, 9 and 12 months of age.

Condition Intervention Phase
Cystic Fibrosis
Dietary Supplement: Docosahexaenoic acid (DHA)
Dietary Supplement: Standard formula (Enfamil)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)

Resource links provided by NLM:

Further study details as provided by University of Massachusetts, Worcester:

Primary Outcome Measures:
  • height and weight for age z-score and human fecal elastase-1 in stool [ Time Frame: one year ]

Secondary Outcome Measures:
  • Secondary End Points: 1. AA/DHA ratio in plasma 2. Chest x-ray film Brasfield scores 3. Serum immune reactive trypsinogen 4. Serum alpha fetoprotein 5. Infant pulmonary function tests (subset analysis) 6. Bayley's scales of childhood development [ Time Frame: 1 year ]

Enrollment: 76
Study Start Date: March 2003
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Infants will be fed formula supplemented with docosahexaenoic acid
Dietary Supplement: Docosahexaenoic acid (DHA)
Infant formula with 0.96% of fatty acids as DHA
Other Name: LIPIL x 3
Placebo Comparator: 2
Infants will be fed standard formula (Enfamil)
Dietary Supplement: Standard formula (Enfamil)
This is a standard, commercially available infant formula.
Other Name: Enfamil

  Show Detailed Description


Ages Eligible for Study:   up to 56 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Infant diagnosed with CF and enrolled by 56 days of life
  • Parental consent obtained

Exclusion Criteria:

  • History of meconium ileus at birth that is resolved without surgical intervention (ie enema)
  • History of bowel resection for any reason
  • Breast feeding
  • Premature birth (<34 weeks gestation)
  • Severe cholestasis (Direct Bilirubin > 2x upper limit of normal for age)
  • Severe hypoalbuminemia (Albumin < 2.5 gm/dl)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00530244

United States, Alabama
UAB/CHS Cystic Fibrosis Center
Birmingham, Alabama, United States, 35233
United States, Georgia
Emory Cystic Fibrosis Center
Atlanta, Georgia, United States, 30322
United States, Iowa
Blank Children's Hospital
Des Moines, Iowa, United States, 50309
United States, Kansas
Cystic Fibrosis Care & Teaching Center
Wichita, Kansas, United States, 67218
United States, Kentucky
Kosair Charities
Louisville, Kentucky, United States, 40202
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Children's Hospital
Boston, Massachusetts, United States, 02115
Baystate Medical Center
Springfield, Massachusetts, United States, 01199
UMass Memorial Healthcare
Worcester, Massachusetts, United States, 01655
United States, Missouri
Children's Mercy Hospital
Kansas City, Missouri, United States, 64108
United States, New Jersey
Monmouth Medical Center
Long Branch, New Jersey, United States, 07740
The Respiratory Center for Children
Morristown, New Jersey, United States, 07962-1956
United States, New York
Albany Medical Center
Albany, New York, United States, 12208
Children's Hospital
Buffalo, New York, United States, 14222
Schneider Children's Hospital
New Hyde Park, New York, United States, 11040
Strong Memorial Hospital
Rochester, New York, United States, 14642
Univesity Medical Center
Stony Brook, New York, United States, 11794
SUNY Upstate Medical Center
Syracuse, New York, United States, 13210
Children's Hospital at Westchester Medical Center
Valhalla, New York, United States, 10595
United States, Ohio
Lewis H Walker CF Pulmonary Center
Akron, Ohio, United States, 44308
Lewis H Walker Cystic Fibrosis Center Division of Pulmonary
Akron, Ohio, United States, 44308
United States, Pennsylvania
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, United States, 19134
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15231
United States, West Virginia
Mountain State University
Morgantown, West Virginia, United States, 26506
Sponsors and Collaborators
University of Massachusetts, Worcester
Cystic Fibrosis Foundation Therapeutics
Principal Investigator: Brian P O'Sullivan, MD University of Massachusetts, Worcester
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Brian O'Sullivan, Study Principle Investigator, University of Massachusetts, Worcester Identifier: NCT00530244     History of Changes
Other Study ID Numbers: OSULLI03A0
Study First Received: September 13, 2007
Last Updated: February 16, 2012

Keywords provided by University of Massachusetts, Worcester:
cystic fibrosis
fatty acids
docosahexaenoic acid
infant formula
pancreatic function

Additional relevant MeSH terms:
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases processed this record on April 21, 2017